Naveen Yalamanchi - Net Worth and Insider Trading
Naveen Yalamanchi Net Worth
The estimated net worth of Naveen Yalamanchi is at least $2 Million dollars as of 2024-11-13. Naveen Yalamanchi is the Director of Rocket Pharmaceuticals Inc and owns about 113,641 shares of Rocket Pharmaceuticals Inc (RCKT) stock worth over $2 Million. Details can be seen in Naveen Yalamanchi's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Naveen Yalamanchi has not made any transactions after 2018-08-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Naveen Yalamanchi
Naveen Yalamanchi Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Naveen Yalamanchi owns 5 companies in total, including Health Sciences Acquisitions Corp 2 (HSAQ) , Rocket Pharmaceuticals Inc (RCKT) , and Immunovant Inc (IMVTU) among others .
Click here to see the complete history of Naveen Yalamanchi’s form 4 insider trades.
Insider Ownership Summary of Naveen Yalamanchi
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HSAQ | Health Sciences Acquisitions Corp 2 | 2020-08-03 | director & Chief Financial Officer |
| RCKT | Rocket Pharmaceuticals Inc | 2018-08-01 | director |
| IMVTU | Immunovant Inc | 2019-05-09 | director & Vice President and CFO |
 | | 2019-05-09 | director & Vice President and CFO |
| | 2020-08-03 | director & Chief Financial Officer |
Naveen Yalamanchi Latest Holdings Summary
Naveen Yalamanchi currently owns a total of 1 stock. Naveen Yalamanchi owns 113,641 shares of Rocket Pharmaceuticals Inc (RCKT) as of August 1, 2018, with a value of $2 Million.
Latest Holdings of Naveen Yalamanchi
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RCKT | Rocket Pharmaceuticals Inc | 2018-08-01 | 113,641 | 16.03 | 1,821,665 |
Holding Weightings of Naveen Yalamanchi
Naveen Yalamanchi Form 4 Trading Tracker
According to the SEC Form 4 filings, Naveen Yalamanchi has made a total of 0 transactions in Rocket Pharmaceuticals Inc (RCKT) over the past 5 years. The most-recent trade in Rocket Pharmaceuticals Inc is the sale of 637 shares on August 1, 2018, which brought Naveen Yalamanchi around $14,014.
Insider Trading History of Naveen Yalamanchi
- 1
Naveen Yalamanchi Trading Performance
Naveen Yalamanchi Ownership Network
Ownership Network List of Naveen Yalamanchi
Ownership Network Relation of Naveen Yalamanchi
Naveen Yalamanchi Owned Company Details
What does Health Sciences Acquisitions Corp 2 do?
Who are the key executives at Health Sciences Acquisitions Corp 2?
Naveen Yalamanchi is the director & Chief Financial Officer of Health Sciences Acquisitions Corp 2. Other key executives at Health Sciences Acquisitions Corp 2 include director & See Remarks David P Hochman , Chief Financial Officer Michael Kaswan , and director & See Remarks Darren Sherman .
Health Sciences Acquisitions Corp 2 (HSAQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Health Sciences Acquisitions Corp 2 (HSAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Health Sciences Acquisitions Corp 2 (HSAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Health Sciences Acquisitions Corp 2 (HSAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Health Sciences Acquisitions Corp 2 Insider Transactions
Naveen Yalamanchi Mailing Address
Above is the net worth, insider trading, and ownership report for Naveen Yalamanchi. You might contact Naveen Yalamanchi via mailing address: 412 West 15th Street, 9th Floor, New York Ny 10019.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
